How Long Does PT-141 Last? Onset, Duration, Frequency

Key takeaways

• After an injection, PT-141 (bremelanotide) peaks in the blood at about one hour and has a half-life of about 2.7 hours (range 1.9 to 4.0), which is why the label says to inject at least 45 minutes before sex.
• In the male laboratory studies, erections began about 30 minutes after a nasal dose and were monitored for up to six hours. For desire, the label states plainly that the duration of the effect is unknown.
• Side effects have their own clocks: nausea starts within an hour and lasts about two; blood pressure rises by up to 6 mmHg, peaks at two to four hours and usually settles within 12.
• The label allows one dose per 24 hours and eight a month, because closer doses add to the blood pressure effect and frequent dosing darkens skin. Most of a dose is cleared in about 14 hours.

How long does PT-141 last? In the blood, briefly: bremelanotide peaks about an hour after an injection and halves every 2.7 hours, so most of a dose is gone within about 14 hours. Its effects run on different clocks: erections in the male studies began about 30 minutes after dosing, nausea lasts about two hours, and the rise in blood pressure takes up to 12 hours to settle. How long the effect on desire lasts is, in the label's own words, unknown. The PT-141 profile covers the drug in full, the guide to peptides for ED and libido puts it in context for men, and PT-141 dosage covers the doses and the injection-versus-spray question.

The timeline after one dose

Onset: how long it takes to work

Blood levels. After a subcutaneous injection the median time to peak is about one hour, within a range of half an hour to an hour; bioavailability is close to 100%, and the abdomen and thigh give the same exposure (Vyleesi label). Nasal doses peak faster, at a median of about 30 minutes (Diamond 2004).

Erections in men. The intranasal studies in healthy men and in men with mild to moderate ED found statistically significant erections at doses above 7 mg, with the first erection about 30 minutes after dosing (Diamond 2004). The injected studies found significant erections above 1 mg in healthy men and at 4 and 6 mg in men whom sildenafil had failed (Rosen 2004); that abstract gives no onset time, but the one-hour peak suggests a similar or slightly longer wait. None of this is an approved use: the label says bremelanotide is not indicated in men.

Desire in women. The label recommends injecting at least 45 minutes before anticipated sex, then says the duration of efficacy is unknown and the optimal window has not been fully characterized; women may adjust the timing based on how they experience the effect and any nausea (Vyleesi label). In the phase 3 trials they were told to inject about 45 minutes beforehand.

Duration: how long the effect lasts

There are three honest answers, depending on what "last" means.

In the blood: a few hours. The mean terminal half-life is about 2.7 hours, ranging from 1.9 to 4.0 hours between people (Vyleesi label). By six hours after the peak, roughly a fifth of the dose remains.

For erections: hours, measured in a laboratory. The male studies measured erections with a rigidity monitor in the hours after a single dose; in the 2005 combination study, recording ran for six hours after dosing and included two 30-minute erotic videos (Diamond 2005). A review of those studies tabulates the results as total minutes per session with at least 60% rigidity at the base of the penis: in healthy men, 49 to 138 minutes after nasal doses of 7 to 20 mg versus 21 on placebo, and 18 to 73 minutes after injected doses of 1 to 10 mg versus 6; in men whom sildenafil had failed, 14 and 17 minutes with at least 80% rigidity after 4 and 6 mg injected versus 2 on placebo (Kim 2021). Those are cumulative minutes during a session, not the length of one erection, and nobody has measured how long the effect lasts at home.

For desire: unknown. The label says so directly. The trials measured desire as a score at the end of 24 weeks, not hour by hour after each dose.

Side effects and how long they last

Source: Vyleesi label. Nausea led 8% of women to stop the drug, 13% took an anti-nausea medicine, and pretreatment with ondansetron did not prevent it.

Frequency: why one dose per 24 hours and eight a month

The limits follow directly from the clocks above. The label says consecutive doses within 24 hours were never shown to work and may add to the blood pressure effect, and that more than eight doses a month were rarely used in the trials and increase both the risk of skin darkening and the share of each month spent with raised blood pressure (Vyleesi label).

Two details from the label show how the blood pressure effect behaves with repeated use. Doses 24 hours apart for up to 16 days did not stack: each dose produced its own transient rise. In an ambulatory study of 127 premenopausal women dosed daily for eight days, average daytime pressure was 1.9 mmHg systolic and 1.7 mmHg diastolic higher, and readings 12 to 24 hours after each dose matched the pre-dose values.

In practice, women in the phase 3 trials used it far less than the ceiling: the median was 10 injections over 24 weeks, mostly two or three a month.

How long you can keep using it. The label's checkpoint is eight weeks: stop if nothing has improved. For longer use, 684 women entered a 52-week open-label extension after the trials and 272 completed it; improvements were sustained in those who stayed, nausea remained the most common drug-related event at 40.4%, and no new safety signals appeared (Simon 2019). There was no placebo group, so it shows how the drug behaves over a year in women who tolerate it, not that it keeps working.

How long it stays in your system

Bremelanotide is broken down by cutting its peptide bonds, and after a radiolabeled dose 64.8% of the radioactivity was recovered in urine and 22.8% in feces (Vyleesi label). With a half-life of 2.7 hours, five half-lives, the usual rule of thumb for near-complete clearance, come to about 14 hours; at the slow end of the measured range, 4.0 hours, they come to about 20 hours. Kidney function matters: exposure rises 1.2-fold with mild, 1.5-fold with moderate and 2-fold with severe kidney impairment, and the label advises caution in severe impairment because nausea and vomiting may be more common. Moderate liver impairment raises exposure 1.7-fold.

Alcohol did not change bremelanotide's blood levels in the label's interaction study of a 20 mg nasal dose, though headache was more common with the combination than with bremelanotide alone.

Bottom line

PT-141 is a short-acting drug with longer-lasting side effects. It peaks within an hour of an injection, is mostly cleared within a day, produced erections in men within about 30 minutes in laboratory studies, and has an effect on desire whose duration nobody has measured. Nausea is a two-hour problem; the blood pressure rise is a twelve-hour one, and it is the reason for the one-dose-per-day and eight-a-month limits. Doses and the units for a compounded vial are in the PT-141 dosage guide.

Frequently asked questions

+−What is the half-life of PT-141?

About 2.7 hours after a subcutaneous injection, with a range of 1.9 to 4.0 hours across people, according to the Vyleesi label. After a nasal dose the early studies measured a half-life of about 1.9 to 2.1 hours. Half of the drug is gone from the blood within about three hours of the peak, which is why bremelanotide is used as needed rather than daily.

+−How long does PT-141 stay in your system?

On average, about 14 hours: it takes roughly five half-lives of 2.7 hours to clear almost all of a dose, and in people at the slow end of the measured range, about 20 hours. That is our arithmetic from the label, not a label statement. Kidney impairment raises exposure 1.5-fold when moderate and 2-fold when severe, so clearance takes longer. About two-thirds of a radiolabeled dose was recovered in the urine.

+−How long does PT-141 take to work?

Blood levels peak about an hour after an injection, which is why the label says to inject at least 45 minutes before anticipated sex. In the male nasal studies, the first erections appeared about 30 minutes after dosing. The label adds that the best timing has not been fully worked out and lets women adjust it based on how they experience the effect and any nausea. Over weeks, the label's checkpoint is eight weeks: stop if nothing has improved.

+−How long does PT-141 nausea last?

In the approval trials, nausea typically began within an hour of the injection and lasted about two hours, though the label notes it can last longer in some people. It is worst with the first dose: 21% of women had it after the first injection and about 3% after later ones. Overall 40% had nausea at some point, 13% took an anti-nausea drug, and 8% stopped because of it.

+−How long does the blood pressure rise from PT-141 last?

Each dose raised systolic pressure by up to 6 mmHg and diastolic by up to 3 mmHg, peaking two to four hours after the injection, with a fall in heart rate of up to 5 beats a minute; both usually returned to baseline within 12 hours. This is why the label forbids a second dose within 24 hours and contraindicates the drug in uncontrolled hypertension and known cardiovascular disease.

+−How often can you take PT-141?

No more than one dose in 24 hours and no more than eight doses a month, per the Vyleesi label. Doses closer together were never shown to work and may add to the blood pressure effect, and more frequent dosing raises the risk of patchy skin darkening: 38% of women dosed daily for eight days developed it. In the trials most women used it two or three times a month.

+−How do you take PT-141?

The approved form is a 1.75 mg autoinjector used under the skin of the abdomen or thigh, at least 45 minutes before anticipated sex. Compounded bremelanotide comes as a vial for injection with an insulin syringe, or as a nasal spray whose dose has never been tested. Dosing detail and a units chart are in our PT-141 dosage guide; the dose on your pharmacy label overrides any chart.

+−What does PT-141 do?

It activates melanocortin receptors in the brain involved in sexual motivation, rather than acting on blood flow like sildenafil. It is approved as Vyleesi for premenopausal women with low sexual desire, where it raised desire scores modestly, and it produced erections in laboratory studies of men in 2004, though it was never approved for men. It also raises blood pressure briefly and can darken patches of skin.

Sources

1. LabelCosette Pharmaceuticals. VYLEESI (bremelanotide injection) prescribing information, revised March 2024. DailyMed. (2024)
2. StudyDiamond LE et al. Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction. Int J Impot Res 2004;16:51-9. (2004)
3. StudyRosen RC et al. Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with an inadequate response to Viagra. Int J Impot Res 2004;16:135-42. (2004)
4. StudyDiamond LE et al. Co-administration of low doses of intranasal PT-141, a melanocortin receptor agonist, and sildenafil to men with erectile dysfunction results in an enhanced erectile response. Urology 2005;65:755-9. (2005)
5. ReviewKim S, Cho MC, Cho SY et al. Novel emerging therapies for erectile dysfunction. World J Mens Health 2021;39:48-64. (2021)
6. StudySimon JA et al. Long-term safety and efficacy of bremelanotide for hypoactive sexual desire disorder. Obstet Gynecol 2019;134:909-17. (2019)